Hims & Hers (NYSE: HIMS ) is changing the way healthcare is administered in the 21st century, which is increasingly reflected by its surging topline. The company grew its 2024 revenue by 69% YoY to $1.5"AWS Certified AI Practitioner Early Adopter"I am a DevOps Engineer for a major, wholly owned subsidiary of a large-cap Fortune 500. I am a true subject-matter expert on the actual buildout, deployment, and maintenance of AI tools and applications. I have increasingly deep knowledge on the science behind gene ...

Core Insights - Hims & Hers Health (HIMS) and Novo Nordisk (NVO) have announced a partnership to enhance obesity care through telehealth, allowing access to Novo Nordisk's FDA-approved weight loss drug Wegovy on Hims & Hers' platform [1][7][15] Company Performance - Hims & Hers stock has surged over 30% in 2025 following the partnership announcement, while Novo Nordisk's stock has declined more than 20% year to date [2] - Hims & Hers has experienced a remarkable stock performance, with shares soaring over 600% in the last three years, compared to Novo Nordisk's 15% increase [3] Sales and Earnings Projections - Hims & Hers total sales are projected to increase by 58% in fiscal 2025 to $2.33 billion, with further growth of 21% expected in FY26 to $2.84 billion [4] - Annual earnings for Hims & Hers are anticipated to rise over 160% this year to $0.72 per share, with FY26 EPS forecasted to increase by 48% to $1.07 [5] EPS Estimates - Hims & Hers has seen positive earnings estimate revisions, with FY25 and FY26 EPS estimates increasing by 14% and 12% respectively in the last 30 days [11] - Novo Nordisk's FY25 EPS estimates have slightly decreased over the last quarter but increased by 1% in the last month, while FY26 estimates have risen by 2% [13] Market Outlook - Novo Nordisk's sales are expected to grow by 18% in FY25 and another 15% in FY26, reaching $57.1 billion, with EPS growth projected at 17% this year and 22% in FY26 to $4.71 per share [8]

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefront. Hims & Hers Health, Inc. (HIMS) and Teladoc Health, Inc. (TDOC) stand out as emerging players in the rapidly evolving digital health space, providing remote consultations and health management solutions to consumers.Hims & Hers is a consumer-first platform transforming the way customers fulfill their health and ...

Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today’s best pick seems to be in the medical sector. It shows investors a major fundamental strength that has been noticed by other major players in the industry, pushing future upside potential higher. Hims & Hers Health TodayHIMSHims & Hers Health$32.11 -2.93 (-8.35%) 52-Week Range$11.20▼$72.98P/E Ratio72.99Price Target$36.92Add to W ...

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 23% to close at $35.04, with trading volume significantly higher than usual, contrasting with a 3.6% loss over the previous four weeks [1][2] Recent Developments - The surge in Hims & Hers Health's shares is linked to the announcement of a deal to sell Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform, allowing U.S. customers to access NovoCare Pharmacy through Hims & Hers for $599 per month [2] Financial Performance Expectations - The company is projected to report quarterly earnings of $0.14 per share, reflecting a year-over-year increase of 180%, with revenues expected to reach $537.85 million, a 93.4% rise from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has been revised 21.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Hims & Hers Health is categorized within the Zacks Medical Info Systems industry, where Health Catalyst (HCAT) is another player, having closed 0.3% higher at $4.07 but showing a -10.4% return over the past month [4]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and nutrition guidance," Hims & Hers said. "We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong por ...

Core Insights - Novo Nordisk is expanding access to its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro, and Life MD, as supply shortages have eased in the U.S. [1][2] - Hims & Hers shares surged 40% in premarket trading, while Novo Nordisk's stock rose 3% following the announcement [2]. Company Strategies - Novo Nordisk aims to capture more patients by collaborating with telehealth companies, as compounding pharmacies face legal restrictions on producing cheaper, unapproved versions of Wegovy [2][3]. - The partnerships with telehealth providers are designed to create a seamless experience for patients, allowing them to access Wegovy directly from their providers [4]. Pricing and Accessibility - Wegovy will be offered at $499 per month through Novo Nordisk's direct-to-consumer online pharmacy, which is about half of its usual list price for uninsured patients [5]. - Hims & Hers will provide Wegovy starting at $599 per month, which includes additional services such as 24/7 care and nutritional guidance [5][6]. Market Context - Hims & Hers has previously offered compounded versions of semaglutide but is now transitioning to the branded Wegovy due to regulatory changes [9]. - The FDA has set deadlines for compounding pharmacies to cease the production of unapproved versions of semaglutide, impacting the availability of alternatives [10].

At PropNotes, we focus on finding high-yield investment opportunities for individual investors.With our background in professional Prop Trading, we make complex concepts easy to understand and offer clear, actionable advice to help you achieve better returns.All of the analysis we produce is designed to help you make smart decisions in the market, backed by expert research you won't find elsewhere.Follow us today and take control of your portfolio.Analyst’s Disclosure: I/we have a beneficial long position i ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -30.9%, compared to the Zacks S&P 500 composite's -8.9% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has lost 16.5%. The key question now is: What could be the stock's fu ...